Objective The original European League Against Rheumatism recommendations for managing fibromyalgia assessed evidence up to 2005. The paucity of studies meant that most recommendations were 'expert opinion'. Methods A multidisciplinary group from 12 countries assessed evidence with a focus on systematic reviews and meta-analyses concerned with pharmacological/nonpharmacological management for fibromyalgia. A review, in May 2015, identified eligible publications and key outcomes assessed were pain, fatigue, sleep and daily functioning. The Grading of Recommendations Assessment, Development and Evaluation system was used for making recommendations. Results 2979 titles were identified: from these 275 full papers were selected for review and 107 reviews (and/or meta-analyses) evaluated as eligible. Based on metaanalyses, the only 'strong for' therapy-based recommendation in the guidelines was exercise. Based on expert opinion, a graduated approach, the following four main stages are suggested underpinned by shared decision-making with patients. Initial management should involve patient education and focus on nonpharmacological therapies. In case of non-response, further therapies (all of which were evaluated as 'weak for' based on meta-analyses) should be tailored to the specific needs of the individual and may involve psychological therapies (for mood disorders and unhelpful coping strategies), pharmacotherapy (for severe pain or sleep disturbance) and/or a multimodal rehabilitation programme (for severe disability). Conclusions These recommendations are underpinned by high-quality reviews and meta-analyses. The size of effect for most treatments is relatively modest. We propose research priorities clarifying who will benefit from specific interventions, their effect in combination and organisation of healthcare systems to optimise outcome.

EULAR revised recommendations for the management of fibromyalgia / G.J. Macfarlane, C. Kronisch, L.E. Dean, F. Atzeni, W. Häuser, E. Flub, E. Choy, E. Kosek, K. Amris, J. Branco, F. Dincer, P. Leino-Arjas, K. Longle, G.M. Mccarthy, S. Makri, S. Perrot, P. Sarzi-Puttini, A. Taylor, G.T. Jones. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 76:2(2017 Feb), pp. 318-328. [10.1136/annrheumdis-2016-209724]

EULAR revised recommendations for the management of fibromyalgia

F. Atzeni;P. Sarzi-Puttini;
2017-02

Abstract

Objective The original European League Against Rheumatism recommendations for managing fibromyalgia assessed evidence up to 2005. The paucity of studies meant that most recommendations were 'expert opinion'. Methods A multidisciplinary group from 12 countries assessed evidence with a focus on systematic reviews and meta-analyses concerned with pharmacological/nonpharmacological management for fibromyalgia. A review, in May 2015, identified eligible publications and key outcomes assessed were pain, fatigue, sleep and daily functioning. The Grading of Recommendations Assessment, Development and Evaluation system was used for making recommendations. Results 2979 titles were identified: from these 275 full papers were selected for review and 107 reviews (and/or meta-analyses) evaluated as eligible. Based on metaanalyses, the only 'strong for' therapy-based recommendation in the guidelines was exercise. Based on expert opinion, a graduated approach, the following four main stages are suggested underpinned by shared decision-making with patients. Initial management should involve patient education and focus on nonpharmacological therapies. In case of non-response, further therapies (all of which were evaluated as 'weak for' based on meta-analyses) should be tailored to the specific needs of the individual and may involve psychological therapies (for mood disorders and unhelpful coping strategies), pharmacotherapy (for severe pain or sleep disturbance) and/or a multimodal rehabilitation programme (for severe disability). Conclusions These recommendations are underpinned by high-quality reviews and meta-analyses. The size of effect for most treatments is relatively modest. We propose research priorities clarifying who will benefit from specific interventions, their effect in combination and organisation of healthcare systems to optimise outcome.
Fibromyalgis/Pain Syndromes; Multidisciplinary team-care; Treatment; Acupuncture Therapy; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Capsaicin; Cognitive Behavioral Therapy; Europe; Evidence-Based Medicine; Exercise Therapy; Fatigue; Fibromyalgia; Human Growth Hormone; Humans; Hydrotherapy; Hypnosis; Manipulation, Chiropractic; Massage; Mind-Body Therapies; Mindfulness; Monoamine Oxidase Inhibitors; Pain; S-Adenosylmethionine; Sensory System Agents; Serotonin Uptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Societies, Medical; Sodium Oxybate; Treatment Outcome; Activities of Daily Living; Practice Guidelines as Topic; Sleep; Rheumatology; Immunology and Allergy; Immunology; Biochemistry, Genetics and Molecular Biology (all)
Settore MED/16 - Reumatologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
318.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 677.81 kB
Formato Adobe PDF
677.81 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/640542
Citazioni
  • ???jsp.display-item.citation.pmc??? 222
  • Scopus 545
  • ???jsp.display-item.citation.isi??? 529
social impact